ClinicalTrials.gg
TerminatedNCT02104336Updated Nov 18, 2020

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

A Phase 2 interventional study of EPI-743 in Pearson Syndrome, sponsored by Edison Pharmaceuticals Inc. Terminated at 4 sites in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-11-18.

Sponsored by Edison Pharmaceuticals Inc (part of PTC Therapeutics) · Phase 2, Interventional, and Treatment

Why this study was terminated
Results from other studies did not support continuation of this trial

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in VLCAD deficiency with a site in United States — 1 open to participants now, 3 under way, none of them phase 3. VLCAD deficiency · United States.

Started
2014
with 2 others
Phase 2
4 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
1 of 12
Edison Pharmaceuticals Inc

Among the 12 studies in VLCAD deficiency with a site in United States, this one is one of 3 that started in 2014, is one of 4 in phase 2, and was the 4th registered.

VLCAD deficiency

26 studies on the registry are indexed under VLCAD deficiency; 6 are open to participants now.

Browse VLCAD deficiency studies →

Open to participants now

1 of the 12 studies in VLCAD deficiency with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 VLCAD deficiency studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in VLCAD deficiency with a site in United States, or all of them as a file.
02

Study summary

Treatment of Pediatric Subjects with Pearson syndrome

Read the detailed description

If effective, treatment with EPI-743 should result in a significant reduction in occurrence of sepsis, metabolic crisis, hepatic failure and transfusion dependence.

03

Conditions studied

  • Pearson Syndrome

Keywords

  • Pearson
  • EPI743
  • EPI-743
  • Vincerinone
  • Mitochondrial disorder
  • Mitochondrial disease
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genetically confirmed diagnosis of Pearson syndrome
  • Age less than 18
  • Availability of medical history for 12 months prior to enrollment
  • Abstention from use of CoQ10, vitamin E, lipoic acid and Idebenone 14 days prior to treatment with EPI-743

Exclusion criteria

Exclusion Criteria:

  • Allergy to EPI-743, sesame oil or vitamin E
  • Clinical history of bleeding/ abnormal PT/
  • Concurrent inborn errors of metabolism
  • Use of anticoagulant medications
  • Participation in any interventional study within 30 days of treatment
  • Use of erythropoietin 30 days prior to trial enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    EPI-743

    15 mg/kg EPI-743 to be administered three times per day for 1 year

    Drug: EPI-743

Interventions

  • EPI-743 is the quinone oxidation product of alpha-tocotrienol

    Also known as: Vincerinone (TM)

06

What researchers measure

Primary outcomes

  1. Occurence of episodes of sepsis, metabolic crisis or hepatic faillure

    Time frame: 1 year

Secondary outcomes

  1. Transfusion avoidance

    Time frame: 1 year

  2. Hematologic function

    Time frame: 1 year

  3. Neuromuscular function

    Neuromuscular function as assessed by Gross Motor Function Measure

    Time frame: 1 year

  4. Disease severity

    Disease severity as assessed by Newcastle Pediatric Mitochondrial Disease Scale

    Time frame: 1 year

  5. Renal function

    Time frame: 1 year

  6. Hepatic function

    Time frame: 1 year

  7. Weight gain

    Time frame: 1 year

  8. Hospitalizations

    Time frame: 1 year

  9. Pancreatic function

    Pancreatic function as assessed by insulin requirement and hemoglobin A1c

    Time frame: 1 year

  10. Mortality

    Time frame: 1 year

Other outcomes

  1. Number of Dose Limiting SAEs

    Any adverse event greater than or equal to grade 3 that is deemed related to treatment with EPI-743 and not related to underlying disease

    Time frame: 1 year

07

Study locations

4 sites
  • Children's Hospital of Orange County
    Orange, California 82868, United States
  • Cleveland Clinic
    Cleveland, Ohio, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Nov 2015, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2014
First posted
Apr 4, 2014
StartActual
Aug 31, 2014
Primary completionActual
Nov 30, 2015
CompletionActual
Feb 29, 2016
Results delay requested
Aug 17, 2020
Last update
Nov 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02104336
Responsible party
Sponsor
First posted
Apr 4, 2014
Start date
Aug 31, 2014
Primary completion
Nov 30, 2015
Completion
Feb 29, 2016
Last update
Nov 18, 2020

Study contacts

Matthew Klein, MD, FACS
study chair · Edison Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion